Medpace director granted 1,110 stock options

Medpace Holdings, Inc. director Cornelius P. McCarthy III received a grant of stock options covering 1,110 shares of common stock at an exercise price of $415.2700 per share.

Rhea-AI Filing Summary

Medpace Holdings, Inc. director Cornelius P. McCarthy III received a grant of stock options covering 1,110 shares of common stock at an exercise price of $415.2700 per share. These options expire on May 15, 2033 and are a compensation-related award, not an open-market purchase.

According to the footnote, the option vests on the earlier of the day immediately preceding the first annual shareholder meeting after the grant date or the first anniversary of the grant, subject to his continued service on the board. Following the reported transactions, he holds 10,324 shares of common stock directly.

Insider Trade Summary

Grant/Award: 1,110 shares

Grant/Award 2 txns

Insider McCarthy Cornelius P. III

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	1,110	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 1,110 contracts (Direct); Common Stock — 10,324 shares (Direct)

Footnotes (1)

1. F1. The option vests on the earlier of (i) the day immediately preceding the date of the first annual meeting of the Issuer following the date of grant, and (ii) the first anniversary of the date of grant, subject to continued service on the board of directors of the Issuer through the vesting date.

Key Figures

Option grant size: 1,110 options Exercise price: $415.2700 per share Option expiration: May 15, 2033 +1 more

4 metrics

Option grant size 1,110 options Stock Option (Right to Buy) granted to director on May 15, 2026

Exercise price $415.2700 per share Conversion or exercise price for 1,110 stock options

Option expiration May 15, 2033 Expiration date for the granted stock options

Shares owned after 10,324 shares Total Medpace common shares directly held after transactions

Key Terms

Stock Option (Right to Buy), exercise price, vests, board of directors

4 terms

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price": "415.2700""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests financial

"The option vests on the earlier of (i) the day immediately preceding"

board of directors financial

"subject to continued service on the board of directors of the Issuer"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Medpace (MEDP) director Cornelius P. McCarthy III receive in this Form 4?

Medpace director Cornelius P. McCarthy III received a grant of stock options for 1,110 shares of common stock. The options are a compensation-related award at an exercise price of $415.2700 per share, not an open-market share purchase or sale.

What is the exercise price and expiration date of the new Medpace (MEDP) stock options?

The granted stock options have an exercise price of $415.2700 per share and expire on May 15, 2033. This defines the price at which the director can buy Medpace common shares before the stated expiration date, subject to vesting conditions.

How and when do the Medpace (MEDP) options granted to the director vest?

The options vest on the earlier of two dates: the day immediately before the first Medpace annual meeting after the grant, or the first anniversary of the grant. Vesting is conditioned on the director’s continued service on the board through the vesting date.

How many Medpace (MEDP) common shares does the director hold after this Form 4?

After the reported transactions, the director holds 10,324 Medpace common shares directly. This figure reflects his direct ownership position in the company’s stock as reported in the Form 4 for the stated date.

Is the Medpace (MEDP) Form 4 transaction a market buy or sell of shares?

No, the Form 4 primarily reports a grant of stock options, categorized as a grant or award acquisition. It is a compensation-related equity award, not an open-market purchase or sale of Medpace common stock by the director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 05:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McCarthy Cornelius P. III

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OHIO 45227

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								10,324	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$415.27	05/15/2026		A		1,110		(1)	05/15/2033	Common Stock	1,110	$0	1,110	D

Explanation of Responses:

1. The option vests on the earlier of (i) the day immediately preceding the date of the first annual meeting of the Issuer following the date of grant, and (ii) the first anniversary of the date of grant, subject to continued service on the board of directors of the Issuer through the vesting date.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for Cornelius P. McCarthy III	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)